company background image
ORNBV

Orion Oyj HLSE:ORNBV Stock Report

Last Price

€36.11

Market Cap

€5.1b

7D

-1.3%

1Y

-29.4%

Updated

05 Dec, 2023

Data

Company Financials +

Orion Oyj

HLSE:ORNBV Stock Report

Mkt Cap: €5.1b

ORNBV Stock Overview

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally.

About the company

ORNBV fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance2/6
Financial Health5/6
Dividends3/6

Rewards

Trading at 43.9% below our estimate of its fair value
Earnings are forecast to grow 19.14% per year

Risk Analysis

Dividend of 4.43% is not well covered by earnings or cash flows
High level of non-cash earnings
Profit margins (14.9%) are lower than last year (26.5%)

Orion Oyj Competitors

Sichuan Kelun Pharmaceutical

SZSE:002422

CN¥41.1b

Shenzhen Salubris Pharmaceuticals

SZSE:002294

CN¥35.5b

Humanwell Healthcare (Group)Ltd

SHSE:600079

CN¥43.2b

Abbott India

BSE:500488

₹491.3b

Price History & Performance

Summary of all time highs, changes and price drops for Orion Oyj
Historical stock prices
Current Share Price€36.11
52 Week High€55.16
52 Week Low€32.89
Beta0.32
1 Month Change-1.58%
3 Month Change-3.66%
1 Year Change-29.36%
3 Year Change-7.98%
5 Year Change22.45%
Change since IPO159.78%

Recent News & Updates

Are Investors Undervaluing Orion Oyj (HEL:ORNBV) By 43%?

Nov 28
Are Investors Undervaluing Orion Oyj (HEL:ORNBV) By 43%?

We Think That There Are More Issues For Orion Oyj (HEL:ORNBV) Than Just Sluggish Earnings

Nov 03
We Think That There Are More Issues For Orion Oyj (HEL:ORNBV) Than Just Sluggish Earnings

Recent updates

Are Investors Undervaluing Orion Oyj (HEL:ORNBV) By 43%?

Nov 28
Are Investors Undervaluing Orion Oyj (HEL:ORNBV) By 43%?

We Think That There Are More Issues For Orion Oyj (HEL:ORNBV) Than Just Sluggish Earnings

Nov 03
We Think That There Are More Issues For Orion Oyj (HEL:ORNBV) Than Just Sluggish Earnings

Orion Oyj (HEL:ORNBV) Could Easily Take On More Debt

Oct 05
Orion Oyj (HEL:ORNBV) Could Easily Take On More Debt

Orion Oyj's (HEL:ORNBV) Intrinsic Value Is Potentially 51% Above Its Share Price

Aug 18
Orion Oyj's (HEL:ORNBV) Intrinsic Value Is Potentially 51% Above Its Share Price

Is Orion Oyj (HEL:ORNBV) Using Too Much Debt?

Jun 21
Is Orion Oyj (HEL:ORNBV) Using Too Much Debt?

A Look At The Intrinsic Value Of Orion Oyj (HEL:ORNBV)

May 16
A Look At The Intrinsic Value Of Orion Oyj (HEL:ORNBV)

Here's Why We Think Orion Oyj (HEL:ORNBV) Is Well Worth Watching

Apr 07
Here's Why We Think Orion Oyj (HEL:ORNBV) Is Well Worth Watching

Orion Oyj (HEL:ORNBV) Could Easily Take On More Debt

Mar 20
Orion Oyj (HEL:ORNBV) Could Easily Take On More Debt

Orion Oyj's (HEL:ORNBV) Upcoming Dividend Will Be Larger Than Last Year's

Feb 12
Orion Oyj's (HEL:ORNBV) Upcoming Dividend Will Be Larger Than Last Year's

A Look At The Intrinsic Value Of Orion Oyj (HEL:ORNBV)

Feb 07
A Look At The Intrinsic Value Of Orion Oyj (HEL:ORNBV)

Is Orion Oyj (HEL:ORNBV) Trading At A 29% Discount?

Oct 13
Is Orion Oyj (HEL:ORNBV) Trading At A 29% Discount?

Orion Oyj (HEL:ORNBV) Seems To Use Debt Quite Sensibly

Sep 22
Orion Oyj (HEL:ORNBV) Seems To Use Debt Quite Sensibly

This Just In: Analysts Are Boosting Their Orion Oyj (HEL:ORNBV) Outlook for This Year

Jul 21
This Just In: Analysts Are Boosting Their Orion Oyj (HEL:ORNBV) Outlook for This Year

Is There An Opportunity With Orion Oyj's (HEL:ORNBV) 34% Undervaluation?

Jul 10
Is There An Opportunity With Orion Oyj's (HEL:ORNBV) 34% Undervaluation?

Does Orion Oyj (HEL:ORNBV) Have A Healthy Balance Sheet?

Jun 14
Does Orion Oyj (HEL:ORNBV) Have A Healthy Balance Sheet?

Are Investors Undervaluing Orion Oyj (HEL:ORNBV) By 34%?

Apr 11
Are Investors Undervaluing Orion Oyj (HEL:ORNBV) By 34%?

Is Orion Oyj (HEL:ORNBV) A Risky Investment?

Mar 09
Is Orion Oyj (HEL:ORNBV) A Risky Investment?

Orion Oyj's (HEL:ORNBV) Intrinsic Value Is Potentially 37% Above Its Share Price

Jan 09
Orion Oyj's (HEL:ORNBV) Intrinsic Value Is Potentially 37% Above Its Share Price

Is Orion Oyj (HEL:ORNBV) Trading At A 31% Discount?

Oct 05
Is Orion Oyj (HEL:ORNBV) Trading At A 31% Discount?

Is Orion Oyj (HEL:ORNBV) Using Too Much Debt?

Aug 19
Is Orion Oyj (HEL:ORNBV) Using Too Much Debt?

Are Investors Undervaluing Orion Oyj (HEL:ORNBV) By 20%?

Jul 07
Are Investors Undervaluing Orion Oyj (HEL:ORNBV) By 20%?

Orion Oyj (HEL:ORNBV) Has A Pretty Healthy Balance Sheet

May 21
Orion Oyj (HEL:ORNBV) Has A Pretty Healthy Balance Sheet

Should Orion Oyj (HEL:ORNBV) Be Part Of Your Dividend Portfolio?

May 03
Should Orion Oyj (HEL:ORNBV) Be Part Of Your Dividend Portfolio?

Can You Imagine How Orion Oyj's (HEL:ORNBV) Shareholders Feel About The 27% Share Price Increase?

Mar 02
Can You Imagine How Orion Oyj's (HEL:ORNBV) Shareholders Feel About The 27% Share Price Increase?

Growth Investors: Industry Analysts Just Upgraded Their Orion Oyj (HEL:ORNBV) Revenue Forecasts By 13%

Feb 09
Growth Investors: Industry Analysts Just Upgraded Their Orion Oyj (HEL:ORNBV) Revenue Forecasts By 13%

Shareholder Returns

ORNBVFI PharmaceuticalsFI Market
7D-1.3%0.5%0.6%
1Y-29.4%3.8%-18.9%

Return vs Industry: ORNBV underperformed the Finnish Pharmaceuticals industry which returned 3.8% over the past year.

Return vs Market: ORNBV underperformed the Finnish Market which returned -18.9% over the past year.

Price Volatility

Is ORNBV's price volatile compared to industry and market?
ORNBV volatility
ORNBV Average Weekly Movement3.4%
Pharmaceuticals Industry Average Movement5.0%
Market Average Movement4.8%
10% most volatile stocks in FI Market8.6%
10% least volatile stocks in FI Market2.9%

Stable Share Price: ORNBV is less volatile than 75% of Finnish stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: ORNBV's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19173,574Liisa Hurmehttps://www.orion.fi

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson’s disease; Simdax for acute decompensated heart failure; and Precedex for intensive care sedative, as well as Fareston for breast cancer. The company also offers Salmeterol/fluticasone Easyhaler; Budesonide/formoterol Easyhaler; Formoterol Easyhaler; Budesonide Easyhaler; Beclomet Easyhaler; and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease.

Orion Oyj Fundamentals Summary

How do Orion Oyj's earnings and revenue compare to its market cap?
ORNBV fundamental statistics
Market Cap€5.11b
Earnings (TTM)€173.20m
Revenue (TTM)€1.16b

29.3x

P/E Ratio

4.4x

P/S Ratio

Is ORNBV overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
ORNBV income statement (TTM)
Revenue€1.16b
Cost of Revenue€528.70m
Gross Profit€634.30m
Other Expenses€461.10m
Earnings€173.20m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Feb 13, 2024

Earnings per share (EPS)1.23
Gross Margin54.54%
Net Profit Margin14.89%
Debt/Equity Ratio23.8%

How did ORNBV perform over the long term?

See historical performance and comparison

Dividends

4.4%

Current Dividend Yield

130%

Payout Ratio